Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(25%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
2
25%
Ph phase_4
2
25%
Ph phase_2
2
25%
Ph not_applicable
2
25%

Phase Distribution

2

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
2(25.0%)
Phase 4Post-market surveillance
2(25.0%)
N/ANon-phased studies
2(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

8

all time

Status Distribution
Active(5)
Completed(1)
Other(2)

Detailed Status

Not yet recruiting3
unknown2
Recruiting2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (25.0%)
Phase 22 (25.0%)
Phase 42 (25.0%)
N/A2 (25.0%)

Trials by Status

unknown225%
recruiting225%
completed113%
not_yet_recruiting338%

Recent Activity

2 active trials
Showing 5 of 8
not_yet_recruitingphase_4

Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury

NCT07518303
recruitingphase_1

Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)

NCT06500793
not_yet_recruitingnot_applicable

The Impact of Nafamostat Mesylate on the Prognosis of Patients With Sepsis-Induced Coagulopathy Undergoing Hemofiltration

NCT06994312
completedphase_1

Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)

NCT05090280
recruitingnot_applicable

The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study

NCT05874674
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT07518303Phase 4

Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury

Not Yet Recruiting
NCT06500793Phase 1

Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)

Recruiting
NCT06994312Not Applicable

The Impact of Nafamostat Mesylate on the Prognosis of Patients With Sepsis-Induced Coagulopathy Undergoing Hemofiltration

Not Yet Recruiting
NCT05090280Phase 1

Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)

Completed
NCT05874674Not Applicable

The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study

Recruiting
NCT06375616Phase 4

Comparison of Nafamostat and Unfractionated Heparin in RRT for Sepsis Associated AKI

Not Yet Recruiting
NCT05555641Phase 2

Efficacy and Safety of Nafamostat Mesylate for VV-ECMO Anticoagulation

Unknown
NCT04418128Phase 2

Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia

Unknown

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8